IONTAS and Teva announce new antibody optimization protocols

IONTAS announced an agreement with Teva Pharmaceuticals to optimize its technology and know-how for human antibodies for use as a biotherapy drug.
Under the terms of the agreement, IONTAS will first use its proprietary technology to provide Teva with a specific set of optimized antibodies. Teva has the option to go into further optimization programs in the future. The protocol also includes screening projects for the biophysical properties of developable antibodies.
Teva recently published an update on its clinical development of Fremanezumab for plexual cluster headaches, and in a Phase III study found that the main endpoint of the average weekly number of congestive headache episodes over a four-week treatment period may not be sufficient.
Dr. John McCafferty, Founder and CEO of IONTAS, commented, "Our experience in antibody discovery and optimization enables us to meet the antibody requirements of our partners' strict properties, and Teva's choice of IONTAS is a validation of this skill and expertise. With our focus on capabilities, affinity, specificity and developmentability, we can produce leading antibodies with a lower risk of chemical, manufacturing and control problems. The
IONTAS provides the biotechnology and pharmaceutical industries with a customized phage presentation library, unique antibody discovery services and technologies. （cyy123.com）